NTU ScholarsDSpace 數位典藏系統是用來獲取、儲存、索引、散佈數位研究資料。https://scholars.lib.ntu.edu.tw:4432024-03-19T04:05:55Z2024-03-19T04:05:55ZThe prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescriptionChen, Rou-TsernLiu, Chih-YuLin, Shu-YungCHIN-CHUNG SHUSheng, Wang-Hueihttps://scholars.lib.ntu.edu.tw/handle/123456789/6410982024-03-19T03:42:42Z2024-03-07T00:00:00Z標題: The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription
作者: Chen, Rou-Tsern; Liu, Chih-Yu; Lin, Shu-Yung; CHIN-CHUNG SHU; Sheng, Wang-Huei
摘要: Regarding clinically-concerning non-standard initial anti-tuberculous (TB) regimens, few studies have examined their prevalence, risk factors and impacts. We recruited patients with drug susceptible TB and non-standard initial anti-TB regimens (NSTB group) and matched them with patients with standard initial regimens (STB group) in a 1:1 ratio. The risk factors and outcomes were analyzed. During the 11-year study period, we analyzed 50 (3.7%) patients with NSTB from a total set of 1337 patients with drug-susceptible TB. Pyrazinamide (60%) was the drug most commonly not prescribed in the NSTB group, followed by ethambutol (34%). Multivariable logistic regression identified independent risk factors as underlying eye disease (adjusted odds ratio [aOR]: 8.869; 95% CI 2.542-30.949; p = 0.001), gout/hyperuricemia (aOR: 4.012 [1.196-13.425]; p = 0.024), and liver disease (aOR: 12.790 [3.981-41.089]; p < 0.001). The NSTB group had longer treatment durations (281 ± 121 vs. 223 ± 63 days; p = 0.003) and more occurrences of treatment interruption (26% vs. 8%; p = 0.021) than the STB group. In conclusion, NSTB occurs in around 3.7% of patients and is associated with longer treatment and more treatment interruption. The risk factors might include underlying liver and eye diseases, and gout. Further studies to improve non-standard initial regimens and prevent negative outcomes are warranted.2024-03-07T00:00:00ZInfluence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary TuberculosisLee, Ho-ShengWei, Yu-FengCHIN-CHUNG SHUhttps://scholars.lib.ntu.edu.tw/handle/123456789/6410972024-03-19T03:40:29Z2023-11-24T00:00:00Z標題: Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis
作者: Lee, Ho-Sheng; Wei, Yu-Feng; CHIN-CHUNG SHU
摘要: The coexistence of lung cancer and tuberculosis is not rare. Rifamycin plays a pivotal role in anti-tuberculosis therapy. However, its potential impact on the liver metabolism of oncology drugs raises concerns. We performed this study to explore whether Rifamycin affects the survival of patients with tuberculosis and lung cancer.2023-11-24T00:00:00Z日本文学は誰のものか ―芥川賞受賞作にみるボーダーレス―SHU-WEN-FAN范淑文https://scholars.lib.ntu.edu.tw/handle/123456789/6410952024-03-19T03:26:38Z2022-01-01T00:00:00Z標題: 日本文学は誰のものか ―芥川賞受賞作にみるボーダーレス―
作者: SHU-WEN-FAN; 范淑文2022-01-01T00:00:00Z一文人としての姿勢―夏目漱石のモノからコトへ―SHU-WEN-FAN范淑文https://scholars.lib.ntu.edu.tw/handle/123456789/6410962024-03-19T03:26:38Z2023-01-01T00:00:00Z標題: 一文人としての姿勢―夏目漱石のモノからコトへ―
作者: SHU-WEN-FAN; 范淑文2023-01-01T00:00:00Z